Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular treatments in Duchenne muscular dystrophy.

Current opinion in pharmacology - 1 Jun 2010

Guglieri Michela, Bushby Kate

Abstract excerpt

Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy and results from mutations in the dystrophin gene. Currently no treatment is available for this devastating condition. Standards of care have been improving and are spreading world-wide, prolonging survival and increasing quality of life, however management of symptoms and complications remains the only interventions that can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Drug Delivery Systems
Share to Dystrophin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DMD gene

Share to Genetic Therapy

Share to Muscular Dystrophy, Duchenne

Share to Mutation

Source

Identifiers

PMID: 20434401
DOI: 10.1016/j.coph.2010.03.005

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular treatments in Duchenne muscular dystrophy.PMID 20434401Read ↗

Therapeutic approaches for Duchenne muscular dystrophy.Semantic proximity Read ↗

Recent Trends in Antisense Therapies for Duchenne muscular dystrophySemantic proximity Read ↗

Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging PharmacotherapiesSemantic proximity Read ↗

Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Duchenne muscular dystrophy: an updated review of common available therapiesSemantic proximity Read ↗

Biological and genetic therapies for the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments.Semantic proximity Read ↗

The DMD gene and therapeutic approaches to restore dystrophin.Semantic proximity Read ↗

Exon-Skipping in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Genetic therapeutic approaches for Duchenne muscular dystrophy.Semantic proximity Read ↗

Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.Semantic proximity Read ↗

Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.